Survey of Ophthalmology
Volume 47 , Pages S53-S64 , August 2002

Effects of Prostaglandins on the Aqueous Humor Outflow Pathways

  • Robert N Weinreb, MD

      Affiliations

    • Corresponding Author InformationReprint address: Robert N. Weinreb, MD, Glaucoma Center, University of California San Diego, 9500 Gilman Drive 0946, La Jolla, CA 92093-0946, USA
    • Glaucoma Center, University of California San Diego, La Jolla, CA USA
    • ,
  • Carol B Toris, PhD

      Affiliations

    • Department of Ophthalmology, University of Nebraska Medical Center, Omaha, NE USA
    • ,
  • B'Ann T Gabelt, MS

      Affiliations

    • Department of Ophthalmology, University of Wisconsin, Madison, WI, USA
    • ,
  • James D Lindsey, PhD

      Affiliations

    • Glaucoma Center, University of California San Diego, La Jolla, CA USA
    • ,
  • Paul L Kaufman, MD

      Affiliations

    • Department of Ophthalmology, University of Wisconsin, Madison, WI, USA

References 

  1. Abramovitz M, Boie Y, Nguyen T, et al.  Cloning and expression of a cDNA for the human prostanoid FP receptor. J Biol Chem. 1994;269:2632–2636
  2. Alm A, Villumsen J. PhXA34, a new potent ocular hypotensive drug. A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers. Arch Ophthalmol. 1991;109:1564–1568
  3. Anthony T, Pierce K, Stamer W, Regan J. Prostaglandin F2 receptors in the human trabecular meshwork. Invest Ophthalmol Vis Sci. 1998;39:315–321
  4. Bárány E. Simultaneous measurement of changing the intraocular pressure and outflow facility in the vervet monkey by constant pressure infusion. Invest Ophthalmol Vis Sci. 1964;3:135–143
  5. Bárány E, Rohen J: Localized contraction and relaxation within the ciliary muscle of the vervet monkey Cercopithecus ethiops, in The Structure of the Eye. II. Symposium. Stuttgart: F. K. Schattauer-Verlag, 1965, pp 287–311
  6. Benbow U, Brinckerhoff CE. The AP-1 site and MMP gene regulation (what is all the fuss about?). Matrix Biol. 1997;15:519–526
  7. Berg A, Ekwall AK, Rubin K, et al.  Effect of PGE1, PGI2, and PGF2 alpha analogs on collagen gel compaction in vitro and interstitial pressure in vivo. Am J Physiol. 1998;274:H663–H671
  8. Bill A. Uveoscleral drainage of aqueous humor (physiology and pharmacology). Prog Clin Biol Res. 1989;312:417–427
  9. Bill A. Blood circulation and fluid dynamics in the eye. Physiol Rev. 1975;55:383–417
  10. Bill A. Effects of longstanding stepwise increments in eye pressure on the rate of aqueous humor formation in a primate (Cercopithecus ethiops). Exp Eye Res. 1971;12:184–193
  11. Bill A. Effects of atropine and pilocarpine on aqueous humour dynamics in cynomolgus monkeys (Macaca irus). Exp Eye Res. 1967;6:120–125
  12. Bill A. Conventional and uveo-scleral drainage of aqueous humour in the cynomolgus monkey (Macaca irus) at normal and high intraocular pressures. Exp Eye Res. 1966;5:45–54
  13. Bill A. Aspects of the drainage of aqueous humor in cats. Arch Ophthalmol. 1962;67:148–155
  14. Camras C: Safety and side-effects of latanoprost, in Weinreb R, Kitazawa Y, Krieglstein G (eds): Glaucoma in the 21st Century. London: Mosby International Ltd, 2000, pp 201–11
  15. Camras CB, Siebold EC, Lustgarten JS, et al.  Maintained reduction of intraocular pressure by prostaglandin F2 alpha- 1-isopropyl ester applied in multiple doses in ocular hypertensive and glaucoma patients. Ophthalmology. 1989;96:1329–1336 discussion 1336–7
  16. Coleman RA, Smith WL, Narumiya S. International Union of Pharmacology classification of prostanoid receptors (properties, distribution, and structure of the receptors and their subtypes). Pharmacol Rev. 1994;46:205–229
  17. Crawford K, Kaufman P, Hubbard W, Woodward D. The DP-receptor agonist SQ27986 raises but does not lower intraocular pressure in ocular normotensive monkeys. J Glaucoma. 1992;1:94–99
  18. Crawford K, Kaufman PL. Pilocarpine antagonizes prostaglandin F2 alpha-induced ocular hypotension in monkeys. Evidence for enhancement of Uveoscleral outflow by prostaglandin F2 alpha. Arch Ophthalmol. 1987;105:1112–1116
  19. Crawford K, Kaufman PL, Gabelt BT. Effects of topical PGF2 alpha on aqueous humor dynamics in cynomolgus monkeys. Curr Eye Res. 1987;6:1035–1044
  20. Crawford KS, Kaufman PL. Dose-related effects of prostaglandin F2-isopropyl ester on intraocular pressure, refraction and pupil diameter in monkeys. Invest Ophthalmol Vis Sci. 1991;32:510–519
  21. Fujino H, Srinivasan D, Pierce KL, Regan JW. Differential regulation of prostaglandin F. 2000;2-receptor(isoforms by protein kinase C Mol Pharmacol 57):353–358
  22. Funck RC, Wilke A, Rupp H, Brilla CG. Regulation and role of myocardial collagen matrix remodeling in hypertensive heart disease. Adv Exp Med Biol. 1997;432:35–44
  23. Gabelt BT, Kaufman PL. The effect of prostaglandin F2 alpha on trabecular outflow facility in cynomolgus monkeys. Exp Eye Res. 1990;51:87–91
  24. Gabelt BT, Kaufman PL. Prostaglandin F2-increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res. 1989;49:389–402
  25. Gabelt BT, Kaufman PL. Prostaglandin F2 alpha increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res. 1989;49:389–402
  26. Galis ZS, Muszynski M, Sukhova GK. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res. 1994;75:181–189
  27. Gaton DD, Sagara T, Lindsey JD, et al.  Increased matrix metalloproteinases 1, 2, and 3 in the monkey uveoscleral outflow pathway after topical prostaglandin F(2 alpha)- isopropyl ester treatment. Arch Ophthalmol. 2001;119:1165–1170
  28. Gaton DD, Sagara T, Lindsey JD, Weinreb RN. Matrix metalloproteinase-1 localization in the normal human uveoscleral outflow pathway. Invest Ophthalmol Vis Sci. 1999;40:363–369
  29. Goh Y, Oshima T, Araie M. Mechanism of intraocular pressure reduction observed after topical application of S-1033 in animals. Jpn J Ophthalmol. 1994;38:228–235
  30. Graves PE, Pierce KL, Bailey TJ, et al.  Cloning of a receptor for prostaglandin F2 alpha from the ovine corpus luteum. Endocrinology. 1995;136:3430–3436
  31. Hayashi M, Yablonski M, Novack G. Trabecular outflow facility determined by fluorophotometry in human subjects. Exp Eye Res. 1989;48:621–625
  32. Inomata H, Bill A, Smelser GK. Unconventional routes of aqueous humor outflow in Cynomolgus monkey (Macaca irus). Am J Ophthalmol. 1972;73:893–907
  33. Jeffrey J. Interstitial collagenases. In:  Parks W,  Mecham R editor. Matrix Metalloproteinases. San Diego, CA: Academic Press; 1998;p. 15–42
  34. Jonat C, Stein B, Ponta H, et al.  Positive and negative regulation of collagenase gene expression. Matrix (Suppl. 1992;1):145–155
  35. Karin M, Liu Z, Zandi E. AP-1 function and regulation. Curr Opin Cell Biol. 1997;9:240–246
  36. Kaufman P. Aqueous humor dynamics. In:  Duane T editors. Clinical Ophthalmology. Philadelphia: Harper & Row; 1985;p. 1–24
  37. Kaufman PF. Assessment of ocular hypotensive mechanisms and additivity of antiglaucoma drugs in humans. Arch Ophthalmol. 1999;117:673–674
  38. Kiriyama M, Ushikubi F, Kobayashi T, et al.  Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997;122:217–224
  39. Kulkarni PS. The role of endogenous eicosanoids in rabbit-intraocular inflammation. J Ocular Pharmacol. 1991;7:227–241
  40. Lake S, Gullberg H, Wahlqvist J, et al.  Cloning of the rat and human prostaglandin F2 alpha receptors and the expression of the rat prostaglandin F2 alpha receptor. FEBS Lett. 1994;355:317–325
  41. Lee PY, Podos SM, Severin C. Effect of prostaglandin F2 alpha on aqueous humor dynamics of rabbit, cat, and monkey. Invest Ophthalmol Vis Sci. 1984;25:1087–1089
  42. Lin A, Smeal T, Binetruy B, et al.  Control of AP-1 activity by signal transduction cascades. Adv Second Messenger Phosphoprotein Res. 1993;28:255–260
  43. Lin CW, Georgescu HI, Evans CH. The role of AP-1 in matrix metalloproteinase gene expression. Agents Actions. 1993;39:C215–C218
  44. Lindsey JD, Kashiwagi K, Boyle D, et al.  Prostaglandins increase proMMP-1 and proMMP-3 secretion by human ciliary smooth muscle cells. Curr Eye Res. 1996;15:869–875
  45. Lindsey JD, Kashiwagi K, Kashiwagi F, Weinreb RN. Prostaglandins alter extracellular matrix adjacent to human ciliary muscle cells in vitro. Invest Ophthalmol Vis Sci. 1997;38:2214–2223
  46. Lindsey JD, Kashiwagi K, Kashiwagi F, Weinreb RN. Prostaglandin action on ciliary smooth muscle extracellular matrix metabolism (implications for uveoscleral outflow). Surv Ophthalmol. 1997;41(Suppl 2):S53
  47. Lindsey JD, To HD, Weinreb RN. Induction of c-fos by prostaglandin F alpha in human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci. 1994;35:242–250
  48. Lutjen-Drecoll E, Tamm E. Morphological study of the anterior segment of cynomolgus monkey eyes following treatment with prostaglandin F2 alpha. Exp Eye Res. 1988;47:761–769
  49. Lütjen-Drecoll E. Normal morphology of the uveoscleral outflow pathways. In:  Alm A,  Weinreb R editor. Uveoscleral Outflow. London: Mosby International Limited; 1998;p. 7–24
  50. Matsuo T, Cynader MS. The EP2 receptor is the predominant prostanoid receptor in the human ciliary muscle. Br J Ophthalmol. 1993;77:110–114
  51. McGetrick JJ, Wilson DG, Dortzbach RK, et al.  A search for lymphatic drainage of the monkey orbit. Arch Ophthalmol. 1989;107:255–260
  52. Millar JC, Kaufman PL. PGF2 alpha/pilocarpine interactions on IOP and accommodation in monkeys. Exp Eye Res. 1995;61:677–683
  53. Miller WL, Weeks JR, Lauderdale JW, Kirton KT. Biological activities of 17-phenyl-18,19,20-trinorprostaglandins. Prostaglandins. 1975;9:9–18
  54. Nagase H, Okada Y. Proteinases and matrix degradation. In:  Kelly WN,  Harris ED,  Ruddy S,  Sledge CB editor. Textbook of Rheumatology. Philadelphia: WB Saunders Co; 1997;p. 323–341
  55. Nagase H, Suzuki K, Morodomi T, et al.  Activation mechanisms of the precursors of matrix metalloproteinases 1, 2, and 3. Matrix (Suppl. 1992;1):237–244
  56. Nagase N. Stromelysins 1 and 2. In:  Parks W,  Mecham R editor. Matrix Metalloproteinases. San Diego: Academic Press; 1998;p. 43–84
  57. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors (structures, properties, and functions). Physiol Rev. 1999;79:1193–1226
  58. Nilsson SF, Samuelsson M, Bill A, Stjernschantz J. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2 -1-isopropylester in the cynomolgus monkey. Exp Eye Res. 1989;48:707–716
  59. Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp Eye Res. 1998;67:179–191
  60. Ocklind A, Lake S, Wentzel P, et al.  Localization of the prostaglandin F2 alpha receptor messenger RNA and protein in the cynomolgus monkey eye. Invest Ophthalmol Vis Sci. 1996;37:716–726
  61. Pederson JE, Gaasterland DE, MacLellan HM. Uveoscleral aqueous outflow in the rhesus monkey (importance of uveal reabsorption). Invest Ophthalmol Vis Sci. 1977;16:1008–1017
  62. Pierce KL, Bailey TJ, Hoyer PB, et al.  Cloning of a carboxyl-terminal isoform of the prostanoid FP receptor. J Biol Chem. 1997;272:883–887
  63. Poyer JF, Millar C, Kaufman PL. Prostaglandin F2 alpha effects on isolated rhesus monkey ciliary muscle. Invest Ophthalmol Vis Sci. 1995;36:2461–2465
  64. Racz P, Ruzsonyi MR, Nagy ZT, Bito LZ. Maintained intraocular pressure reduction with once-a-day application of a new prostaglandin F2 alpha analogue (PhXA41). An in-hospital, placebo-controlled study. Arch Ophthalmol. 1993;111:657–661
  65. Rittig M, Lutjen-Drecoll E, Rauterberg J, et al.  Type-VI collagen in the human iris and ciliary body. Cell Tissue Res. 1990;259:305–312
  66. Rosenberg GA. Matrix metalloproteinases in brain injury. J Neurotrauma. 1995;12:833–842
  67. Sagara T, Gaton DD, Lindsey JD, et al.  Reduction of collagen type I in the ciliary muscle of inflamed monkey eyes. Invest Ophthalmol Vis Sci. 1999;40:2568–2576
  68. Sagara T, Gaton DD, Lindsey JD, et al.  Topical prostaglandin F2 alpha treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Arch Ophthalmol. 1999;117:794–801
  69. Sakamoto K, Ezashi T, Miwa K, et al.  Molecular cloning and expression of a cDNA of the bovine prostaglandin F2 alpha receptor. J Biol Chem. 1994;269:3881–3886
  70. Schachtschabel U, Lindsey JD, Weinreb RN. The mechanism of action of prostaglandins on uveoscleral outflow. Curr Opin Ophthalmol. 2000;11:112–115
  71. Serle JB, Podos SM, Kitazawa Y, Wang RF. A comparative study of latanoprost (Xalatan) and isopropyl unoprostone (Rescula) in normal and glaucomatous monkey eyes. Jpn J Ophthalmol. 1998;42:95–100
  72. Shapiro SD, Kobayashi DK, Pentland AP, Welgus HG. Induction of macrophage metalloproteinases by extracellular matrix. Evidence for enzyme- and substrate-specific responses involving prostaglandin-dependent mechanisms. J Biol Chem. 1993;268:8170–8175
  73. Shaw BR, Lindsey JD, Weinreb RN. Prostaglandin release in a perfused human anterior segment model. J Glaucoma. 1993;2:239–243
  74. Sjoquist B, Johansson A, Stjernschantz J. Pharmacokinetics of latanoprost in the cynomolgus monkey. 3rd communication (tissue distribution after topical administration on the eye studied by whole body autoradiography. Glaucoma Research Laboratories). Arzneimittel-Forschung. 1999;49:240–249
  75. Sjöquist B, Almeård B, Khalifeh V, Alm A. The bioavailability of Xalatan in the human eye. Invest Ophthalmol Vis Sci. 1997;38(Suppl):S248; [abstract]
  76. Stjernschantz J, Nilsson SF, Astin M. Vasodynamic and angiogenic effects of eicosanoids in the eye. Prog Clin Biol Res. 1989;312:155–170
  77. Stjernschantz J, Selen G, Astin M, Resul B. Microvascular effects of selective prostaglandin analogues in the eye with special reference to latanoprost and glaucoma treatment. Prog Retin Eye Res. 2000;19:459–496
  78. Stjernschantz J, Selen G, Sjoquist B, Resul B. Preclinical pharmacology of latanoprost, a phenyl-substituted PGF2 alpha analogue. Adv Prostaglandin Thromboxane Leukot Res. 1995;23:513–518
  79. Stjernschantz J, Selén G, Ocklind A, Resul B. Effects of latanoprost and related analogues. In:  Alm A,  Weinreb R editor. Uveoscleral Outflow. Biology and Clinical Aspects. London: Mosby-Wolfe Medical Communications; 1998;p. 57–72
  80. Sugimoto Y, Hasumoto K, Namba T, et al.  Cloning and expression of a cDNA for mouse prostaglandin F receptor. J Biol Chem. 1994;269:1356–1360
  81. Tamm E, Rittig M, Lutjen-Drecoll E: [Electron microscopy and immunohistochemical studies of the intraocular pressure lowering effect of prostaglandin F2 alpha]. Fortschr Ophthalmol 87:623–9, 1990
  82. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology. 1993;100:1297–1304
  83. Toris CB, Camras CB, Yablonski ME, Brubaker RF. Effects of exogenous prostaglandins on aqueous humor dynamics and blood–aqueous barrier function. Surv Ophthalmol. 1997;41(Suppl 2):S69–S75
  84. Toris CB, Gregerson DS, Pederson JE. Uveoscleral outflow using different-sized fluorescent tracers in normal and inflamed eyes. Exp Eye Res. 1987;45:525–532
  85. Toris CB, Pederson JE. Aqueous humor dynamics in experimental iridocyclitis. X Adv Prostaglandin Thromboxane Leukot Res. 1987;28:477–481
  86. Toris CB, Pederson JE. Effect of intraocular pressure on uveoscleral outflow following cyclodialysis in the monkey eye. Invest Ophthalmol Vis Sci. 1985;26:1745–1749
  87. Toris CB, Yablonski ME, Wang YL, Camras CB. Aqueous humor dynamics in the aging human eye. Am J Ophthalmol. 1999;127:407–412
  88. Toris CB, Yablonski ME, Wang YL, Hayashi M. Prostaglandin A2 increases uveoscleral outflow and trabecular outflow facility in the cat. Exp Eye Res. 1995;61:649–657
  89. Van Alphen GW, Wilhelm PB, Elsenfeld PW. The effect of prostaglandins on the isolated internal muscles of the mammalian eye, including man. Doc Ophthalmol. 1977;42:397–415
  90. Wang RF, Lee PY, Mittag TW, et al.  Effect of 8-iso prostaglandin E2 on aqueous humor dynamics in monkeys. Arch Ophthalmol. 1998;116:1213–1216
  91. Wang TH, Lindsey JD, Weinreb RN. Laminin subtype distribution in the human ciliary muscle. Invest Ophthalmol Vis Sci. 1994;35:3640–3648
  92. Weinreb R, Mitchell M, Alvarado J, Polansky J. Glucocorticoid regulation of eicosanoid biosynthesis in cultured human trabecular cells. In:  Ticho UDR editors. Recent Advances in Glaucoma. Amsterdam: Excerpta Medica—Elsevier Science Publishers B.V; 1984;p. 213–218
  93. Weinreb RN. Enhancement of scleral macromolecular permeability with prostaglandins. Trans Am Ophthalmol Soc. 2001;99:319–343
  94. Weinreb RN, Kashiwagi K, Kashiwagi F, et al.  Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci. 1997;38:2772–2780
  95. Weinreb RN, Kim DM, Lindsey JD. Propagation of ciliary smooth muscle cells in vitro and effects of prostaglandin F2 alpha on calcium efflux. Invest Ophthalmol Vis Sci. 1992;33:2679–2686
  96. Weinreb RN, Lindsey J, Luo XX, Wang T-H. Extracellular matrix of the human ciliary muscle. J Glaucoma. 1994;3:70–78
  97. Weinreb RN, Mitchell MD. Prostaglandin production by cultured cynomolgus monkey trabecular meshwork cells. Prostaglandins Leukot Essent Fatty Acids. 1989;36:97–100
  98. Weinreb RN, Mitchell MD, Polansky JR. Prostaglandin production by human trabecular cells (in vitro inhibition by dexamethasone). Invest Ophthalmol Vis Sci. 1983;24:1541–1545
  99. Woessner JF. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991;5:2145–2154
  100. Wood RL, Koseki T, Kelly DE. Uveoscleral permeability to intracamerally infused ferritin in eyes of rabbits and monkeys. Cell Tissue Res. 1992;270:559–567
  101. Woodward DF, Lawrence RA, Fairbairn CE, et al.  Intraocular pressure effects of selective prostanoid receptor agonists involve different receptor subtypes according to radioligand binding studies. J Lipid Mediat. 1993;6:545–553
  102. Ziai N, Dolan JW, Kacere RD, Brubaker RF. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol. 1993;111:1351–1358

☆ Supported in part by NIH grants EY05590 (RNW) and EY02698 (PLK) and unrestricted grants from Research to Prevent Blindness, Inc., New York, NY (University of California San Diego, University of Nebraska, University of Wisconsin). Johan Stjernschantz, M.D, Ph.D. critically reviewed the manuscript. The authors reported no proprietary or commercial interest in any product mentioned or concept discussed in this article.

PII: S0039-6257(02)00306-5

Survey of Ophthalmology
Volume 47 , Pages S53-S64 , August 2002

Article Tools

* Image Usage & Resolution